An observational study in Diabetes, sponsored by University of Florida. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.
Sponsored by University of Florida · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Diabetes Mellitus by University of Florida — 3 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus · University of Florida.
Among the 15 studies in Diabetes Mellitus by University of Florida, this one is one of 2 that started in 2026, is one of 3 observational ones, and was the 15th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →3 of the 15 studies in Diabetes Mellitus by University of Florida are open now, in 1 country. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 25+ · Women only · Healthy volunteers
University of Florida · Sites in United States
Ages 20–75
By country, each count listing its studies:
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18 is below the median of 246 across 1,935 observational studies indexed under Diabetes Mellitus.
Median enrollment 83 across the 12 interventional studies, 18 across the 3 observational. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Florida is the lead sponsor of 1,290 studies on the registry; 202 are open to participants now.
Of its 181 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
1 of the studies in Diabetes Mellitus by University of Florida that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05561595University of FloridaTransdiagnostic Intervention to Reduce Internalized Health-Related Stigma | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Diabetes Mellitus by University of Florida, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Extension for Community Health Outcomes Diabetes FQHC will provide tele-education to primary care providers (PCP) in Federally Qualified Health Centers in the U.S. using the "hub" and "spoke" training model established in the Project ECHO model. Participating FQHCs (called "spokes") will receive twice monthly tele-education sessions delivered by UF's "hub" team in a 6-month program. The program will be evaluated using pre/posttest provider-level surveys and center-level aggregate data in a stepped-wedge trial design with 3 cohorts of FQHCs. The primary outcomes are the proportion of people >9% HbA1c and technology use (CGM and insulin pump).
We will implement a national ECHO Diabetes FQHC program by offering a 6-month tele-education intervention that includes: (1) a virtual orientation and onboarding for FQHCs (2) one-hour tele-ECHO sessions twice monthly with continuing medical education (CME) credits provided (3) real-time support with complex medical decision-making and (4) access to an online repository of diabetes resources for PCPs. The 'hub' team delivering the ECHO Diabetes FQHC program are a nationally recognized multidisciplinary team of adult and pediatric endocrinologists, a clinical health psychologist, Certified Diabetes Care and Education Specialists (CDCES), a registered dietitian, a Certified Exercise Physiologist (CEP), a medical sociologist, PCPs, and health services researchers.
We will evaluate the ECHO Diabetes FQHC program with a stepped-wedge design. This proposal will leverage and expand on key community partnerships established through ECHO Diabetes with two Health Center Controlled Networks (HCCNs), HealthChoiceNetwork (HCN) and AllianceChicago (AC) to accomplish both specific aims. These two Health Center Controlled Networks (HCCNs) have over 100 FQHCs in 29 different states and hold a central data repository for over 7 million unduplicated patients seen for care across these locations. 18 new "spokes" will be recruited from HCN and AC's national network. Covariate-constrained randomization will be used to assign spokes to three cohorts that will have staggered and phased entry into the program in 6-month intervals. Pre- and post-intervention data will be collected at the provider-level and center-level (i.e., "spoke-level") and housed using REDCap® as a central data repository. Provider-level data will include pre and post surveys assessing confidence and knowledge in diabetes care as well as self-reported diabetes care practices. Spoke-level data will include aggregate Health Effectiveness Data and Information Set (HEDIS) metrics for diabetes, Uniform Data System (UDS) metrics for diabetes, mean HbA1c for demographic subgroups, diabetes technology use (CGM and insulin pumps), and referrals for GLP1 and SGL2 medications.
All people 18 and older with diabetes (T1D, T2D) seen for care at participating Federally Qualified Health Centers.
Inclusion Criteria: Federally Qualified Health centers (spokes) are eligible to participate that are part of Health Choice Network (HCN) or Alliance Chicago (AC). All people living with diabetes 18 and older are included in aggregate data sharing to evaluate outcomes.
-
Exclusion Criteria:
6-8 Federally Qualified Health Centers that participate in the ECHO Diabetes tele-education program for PCPs
Behavioral: ECHO Diabetes tele-education
6-8 Federally Qualified Health Centers that participate in the ECHO Diabetes tele-education program for PCPs
Behavioral: ECHO Diabetes tele-education
6-8 FQHCs that participate in the ECHO Diabetes tele-education program for PCPs
Behavioral: ECHO Diabetes tele-education
All cohorts will be given the ECHO Diabetes tele-education program -- one hour sessions twice monthly for 6 months for PCP in FQHCs
HEDIS >9% HbA1c
Proportion of FQHC population with \>9% HbA1c
Time frame: From baseline to 12-months following
Technology Use
CGM and Pump Use
Time frame: From baseline to 12-months following
Plan to share: Yes — Aggregate data will be shared upon reasonable requests made to project PIs
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Upon publication of data or per request of journals via the publication process
Access criteria: Any one making a reasonable request for data -- all data is aggregated and do not include PHI or identifiers
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jul 2028, 30 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.